Garth Cruickshank

1.2k total citations
23 papers, 899 citations indexed

About

Garth Cruickshank is a scholar working on Genetics, Molecular Biology and Oncology. According to data from OpenAlex, Garth Cruickshank has authored 23 papers receiving a total of 899 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Genetics, 6 papers in Molecular Biology and 6 papers in Oncology. Recurrent topics in Garth Cruickshank's work include Glioma Diagnosis and Treatment (13 papers), PARP inhibition in cancer therapy (4 papers) and Brain Metastases and Treatment (3 papers). Garth Cruickshank is often cited by papers focused on Glioma Diagnosis and Treatment (13 papers), PARP inhibition in cancer therapy (4 papers) and Brain Metastases and Treatment (3 papers). Garth Cruickshank collaborates with scholars based in United Kingdom, Germany and United States. Garth Cruickshank's co-authors include A. Detta, Paul Workman, R Rampling, Alexander D. Lewis, Sara A. Fitzsimmons, James Galea, Patrick Garland, V. Hugh Perry, Delphine Boche and Jessica L. Teeling and has published in prestigious journals such as Journal of Clinical Oncology, NeuroImage and Cancer Research.

In The Last Decade

Garth Cruickshank

23 papers receiving 882 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Garth Cruickshank United Kingdom 15 345 305 239 179 166 23 899
Sarah Lapointe Canada 5 485 1.4× 438 1.4× 312 1.3× 125 0.7× 134 0.8× 18 1.1k
Ichiyo Shibahara Japan 19 255 0.7× 576 1.9× 181 0.8× 195 1.1× 169 1.0× 73 1.0k
Stewart G. Neill United States 16 417 1.2× 259 0.8× 126 0.5× 98 0.5× 153 0.9× 57 978
Nancy Ann Oberheim Bush United States 13 319 0.9× 388 1.3× 198 0.8× 87 0.5× 127 0.8× 47 928
Bakhtiar Yamini United States 20 487 1.4× 269 0.9× 317 1.3× 158 0.9× 55 0.3× 44 1.0k
David Cory Adamson United States 15 481 1.4× 344 1.1× 165 0.7× 162 0.9× 51 0.3× 31 992
Eva María Corrales-García Spain 7 270 0.8× 375 1.2× 215 0.9× 88 0.5× 133 0.8× 12 754
Satoru Osuka Japan 21 677 2.0× 390 1.3× 314 1.3× 355 2.0× 96 0.6× 42 1.3k
Dieter Lemke Germany 15 403 1.2× 365 1.2× 175 0.7× 247 1.4× 49 0.3× 24 882
Thomas Viel France 22 397 1.2× 172 0.6× 190 0.8× 157 0.9× 236 1.4× 43 1.2k

Countries citing papers authored by Garth Cruickshank

Since Specialization
Citations

This map shows the geographic impact of Garth Cruickshank's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Garth Cruickshank with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Garth Cruickshank more than expected).

Fields of papers citing papers by Garth Cruickshank

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Garth Cruickshank. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Garth Cruickshank. The network helps show where Garth Cruickshank may publish in the future.

Co-authorship network of co-authors of Garth Cruickshank

This figure shows the co-authorship network connecting the top 25 collaborators of Garth Cruickshank. A scholar is included among the top collaborators of Garth Cruickshank based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Garth Cruickshank. Garth Cruickshank is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
McConville, Christopher, et al.. (2024). Local Delivery of Irinotecan to Recurrent GBM Patients at Reoperation Offers a Safe Route of Administration. Cancers. 16(17). 3008–3008. 2 indexed citations
3.
Vargas‐Caballero, Mariana, et al.. (2022). Vagus Nerve Stimulation as a Potential Therapy in Early Alzheimer’s Disease: A Review. Frontiers in Human Neuroscience. 16. 866434–866434. 52 indexed citations
4.
Detta, A., Garth Cruickshank, C. Ryan Miller, et al.. (2020). Development and in vivo evaluation of Irinotecan-loaded Drug Eluting Seeds (iDES) for the localised treatment of recurrent glioblastoma multiforme. Journal of Controlled Release. 324. 1–16. 14 indexed citations
5.
Hanna, Catherine, Kathreena M. Kurian, Karin Williams, et al.. (2020). Pharmacokinetics, safety, and tolerability of olaparib and temozolomide for recurrent glioblastoma: results of the phase I OPARATIC trial. Neuro-Oncology. 22(12). 1840–1850. 98 indexed citations
6.
Eales, Katherine L., et al.. (2018). Verteporfin selectively kills hypoxic glioma cells through iron-binding and increased production of reactive oxygen species. Scientific Reports. 8(1). 14358–14358. 26 indexed citations
7.
Cruickshank, Garth, et al.. (2018). Primary and metastatic brain tumours in adults: summary of NICE guidance. BMJ. 362. k2924–k2924. 21 indexed citations
8.
Cruickshank, Garth, et al.. (2018). Delayed central nervous system manifestation of Chikungunya virus with magnetic resonance T2 weighted imaging high signal changes—a case report. Journal of Surgical Case Reports. 2018(6). rjy134–rjy134. 2 indexed citations
9.
Cruickshank, Garth, et al.. (2018). Local Delivery Of Irinotecan To Recurrent Glioblastoma At Reoperation Offers A Safe Therapeutic Advantage Over Systemic Delivery. Neuro-Oncology. 20(suppl_1). i1–i1. 5 indexed citations
10.
Chalmers, Anthony J., Garth Cruickshank, Laurence Dunn, et al.. (2017). ACTR-16. RESULTS OF THE OPARATIC TRIAL: A PHASE I DOSE ESCALATION STUDY OF OLAPARIB IN COMBINATION WITH TEMOZOLOMIDE (TMZ) IN PATIENTS WITH RELAPSED GLIOBLASTOMA (GBM). Neuro-Oncology. 19(suppl_6). vi4–vi4. 14 indexed citations
11.
Cruickshank, Garth, et al.. (2016). Investigating the impact of headaches on the quality of life of patients with glioblastoma multiforme: a qualitative study. BMJ Open. 6(11). e011616–e011616. 11 indexed citations
12.
13.
Hill, Victoria, Thoraia Shinawi, Christopher J. Ricketts, et al.. (2014). Stability of the CpG island methylator phenotype during glioma progression and identification of methylated loci in secondary glioblastomas. BMC Cancer. 14(1). 506–506. 18 indexed citations
14.
Shinawi, Thoraia, Victoria Hill, Dietmar Krex, et al.. (2013). DNA methylation profiles of long- and short-term glioblastoma survivors. Epigenetics. 8(2). 149–156. 93 indexed citations
15.
Galea, James, Garth Cruickshank, Jessica L. Teeling, et al.. (2012). The intrathecal CD163‐haptoglobin–hemoglobin scavenging system in subarachnoid hemorrhage. Journal of Neurochemistry. 121(5). 785–792. 92 indexed citations
16.
Price, Stephen J., et al.. (2012). NICE guidance on the use of carmustine wafers in high grade gliomas: a national study on variation in practice. British Journal of Neurosurgery. 26(3). 331–335. 17 indexed citations
17.
Natalwala, Ammar, et al.. (2011). Comparison of time taken from initial presentation to histological diagnosis of Glioblastoma Multiforme (GBM) in Birmingham, United Kingdom and Strasbourg, France. Clinical Neurology and Neurosurgery. 113(5). 358–361. 4 indexed citations
18.
Detta, A. & Garth Cruickshank. (2009). l-Amino Acid Transporter-1 and Boronophenylalanine-Based Boron Neutron Capture Therapy of Human Brain Tumors. Cancer Research. 69(5). 2126–2132. 106 indexed citations
19.
Detta, A., et al.. (2003). Proliferative activity and in vitro replication of HSV1716 in human metastatic brain tumours. The Journal of Gene Medicine. 5(8). 681–689. 20 indexed citations
20.
Rampling, R, Garth Cruickshank, Alexander D. Lewis, Sara A. Fitzsimmons, & Paul Workman. (1994). Direct measurement of pO2 distribution and bioreductive enzymes in human malignant brain tumors. International Journal of Radiation Oncology*Biology*Physics. 29(3). 427–431. 242 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Sarah Lapointe Breakdown of academic impact, for papers by Ichiyo Shibahara Breakdown of academic impact, for papers by Stewart G. Neill Breakdown of academic impact, for papers by Nancy Ann Oberheim Bush Breakdown of academic impact, for papers by Bakhtiar Yamini Breakdown of academic impact, for papers by David Cory Adamson Breakdown of academic impact, for papers by Eva María Corrales-García Breakdown of academic impact, for papers by Satoru Osuka Breakdown of academic impact, for papers by Dieter Lemke Breakdown of academic impact, for papers by Thomas Viel
Rankless by CCL
2026